Currently, five long-lasting GLP-1 analogs have been approved by the FDA and the European Medicines Agency (EMA) for the treatment of Type 2 diabetes (T2D): exenatide twice-daily (Byetta®, Amylin/Lilly) and exenatide once-weekly (Bydureon®, Amylin/Lilly) are based on exendin-4; liraglutide once daily (Victoza®, Novo Nordisk), Lixisenatide once daily (Lyxumia®, Sanofi) and Albiglutide once-weekly (Tanzeum®/Eperzan®, GSK) are based on the structure of native GLP-1. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.